Articles
AZASITE Phase II trial results for blepharitis
March 26th 2010Used for the treatment of blepharitis, AZASITE (azitthromycin ophthalmic solution) from Inspire Pharmaceuticals Inc., was used in two clinical trials in patients with anterior blepharitis. One trial had a two-week treatment period, the other trial a four-week treatment period.
Sight restored by subretinal implant shows promise
March 25th 2010In results due to be presented at the ARVO meeting in May Retina Implant says its first human clinical trial has exceeded its expectations with some patients able to see objects and shapes so clearly they were able to combine letters to form words and recognize foreign objects.
Ultralase Presents New Treatment Results At Winter ESCRS 2010, Budapest
March 16th 2010LEEDS, England -- Ultralase, the vision correction specialist, presented its first set of results for a new treatment, Ultraelite, at the recent Winter meeting of the European Society of Cataract and Refractive Surgeons in Budapest.
Study suggests the potential long-term benefits of DSAEK may outweigh the initial cell loss
March 15th 2010One year post-surgery, patients who underwent Descemet's stripping automated endothelial keratoplasty (DSAEK) experienced greater cell loss overall compared to those who underwent penetrating keratoplasty (PKP), according to a new analysis of data collected from the Cornea Donor Study (CDS) Investigator Group's 2008 Specular Microscopy Ancillary Study (SMAS).
Leber's congenital amaurosis sufferers could benefit from gene therapy trial
March 11th 2010Last year a human trial involving administering gene therapy to Leber's congenital amaurosis (LCA) patients produced improvements in 12 children and young adults. The same researchers then conducted an animal study that found that a second injection into the previously untreated eye, was safe and effective with no signs of interference from immune reactions from the earlier injection.
Anti-VEGF for AMD a top advancement
February 28th 2010San Francisco?Anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration represent the most significant advancement in ophthalmology over the past decade, according to 52% of respondents to an online survey of members of the American Academy of Ophthalmology conducted in December.
Wet AMD drug enters Phase I trial
February 27th 2010Palomid 529 (P529) is to enter its Phase I trial in patients with AMD. A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients with Advanced Neovascular Age-Related Macular Degeneration will according to Paloma Pharmaceuticals, be a dose-ranging study for safety but will also have an objective measure for efficacy.
VEGF Trap-Eye shows positive results in a phase 2 study in patients with diabetic macular oedema
February 24th 2010VEGF Trap-Eye, the fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related Placental Growth Factor (PIGF), has shown positive results in a Phase 2 study in patients with diabetic macular oedema (DME.
EMA approval sought for non-infectious uveitis drug
February 18th 2010LUVENIQ (LX211; oral voclosporin) has been filed for approval by the European Medicines Agency (EMA) and the US's Food and Drug Administration by Lux Biosciences. The drug is aimed at treatment of non-infectious uveitis for the intermediate or posterior segments of the eye.
Potential of microplsamin to improve the treatment of a range of back of the eye diseases
February 17th 2010A paper entitled A Placebo-Controlled Trial of Microplasmin Intravitreous Injection to Facilitate Posterior Vitreous Detachment Before Vitrectomy has been published online ahead of print in Ophthalmology.
